The Novo Nordisk Inc. (NNI) Investigator Sponsored Studies (ISS) Program will accept protocols within our current areas of interest (AOI) as noted below. This is a competitive process. Incomplete submissions or protocols that are not within the scope of these AOIs/have low relevance to the thereaputic area may be rejected without further review. Submissions will be reviewed by the Novo Nordisk teams on both the US (NNI) and Global level. Decisions will be made based on scientific merit and strategic fit. Please review the submission requirements and abide by the timelines as outlined below. The program requests that investigators specify how they will support enrollment of diverse populations in the study.
Please note that all new clinical ISS applications requesting oral Semaglutide are currently on pause and not being accepted.
Women’s health
Obstructive Sleep apnea
Weight loss maintenance
Drug switching (between anti-obesity medications)
Effects of intentional weight loss on body composition related to:
Effects of GLP1 on gastric emptying
Cancer with 2.4mg primary and secondary prevention
Addictive disorders
Obesity subpopulations:
Obesity-related comorbidities including but not limited
to:
Obesity in relation to:
Other:
Open: March 17, 2025
Closes: June 1, 2025 @ 11:59pm ET
August/September 2025